BTW results out Aug 19. No surprises expected, should be...

BTW results out Aug 19.
No surprises expected, should be marginally under last half which included a capital payment from German contract. Growth been very incremental but definitely on a rising trajectory as more contracts kick in.
The key is that their technology advantage enables them to charge twice as much as competitors.
Even so they have landed 8 of last 9 mandates they have addressed. Their penetration of US radiology is about 1%.
I expect revenue and dividends to ramp in 12-18 months.
Seems the general market is becoming aware of the potential. Still only a $600m mcap and available shares approx 30m.
High margins, no debt, free cash flow with massive growth potential and founders own 60%
Those saying they don't think there's value here are not basing it on anything but recent price action.
Someone shelled out well over $1m today buying 195k shares in 2 lots. Interesting.
Course it may pull back, but I'm comfortable it will be higher by Xmas. Assuming no GFC repetition.